Phase Ib Trial of M1774 and ZEN-3694 in Recurrent Ovarian and Endometrial Cancer
A phase Ib trial is underway to evaluate the safety and efficacy of M1774 combined with ZEN-3694 in recurrent ovarian and endometrial cancer.
Asset / Drug
Drug and asset intelligence for ZEN-3694 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.